Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"SHL Medical AG","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MoonLake Immunotherapeutics and SHL Medical Collaborate To Jointly Develop An Autoinjector For Sonelokimab Supply","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by SHL Medical AG

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The collaboration aims to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody® M1095 (sonelokimab) by using SHL Medical's market-proven Molly® modular platform technology.

            Lead Product(s): Sonelokimab,Adalimumab

            Therapeutic Area: Immunology Product Name: M1095

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: MoonLake Immunotherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY